Join the Jubbonti group to help and get support from people like you.
Jubbonti News
Monthly News Roundup - February 2025
FDA Updates Izervay Label to Lengthen Treatment Duration for Geographic Atrophy Izervay (avacincaptad pegol) from Astellas is now FDA-approved without a limitation on duration of dosing, allowing...
Denosumab Increases Cardiovascular Risk in Dialysis-Dependent Patients
TUESDAY, Jan. 7, 2025 – For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a greater preventive effect on fractures but an increased risk for major adverse...
Risk for Emergently Treated Hypocalcemia With Denosumab Rises With CKD Stage
TUESDAY, Nov. 19, 2024 – For patients with chronic kidney disease (CKD), the risk for emergently treated hypocalcemia with denosumab increases with worsening CKD stage, according to a study...
FDA Approves Jubbonti (denosumab-bddz), an Interchangeable Biosimilar to Prolia
Basel, March 5, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration (FDA) approved Jubbonti, (denosumab-bbdz), an i...